metformin exercise training adaptation

Memo — SGLT2i vs Metformin under Endurance Exercise

Alpha (1 sentence): The same drug class anchor ("antidiabetes agent + exercise") splits by compound — dapagliflozin lets adaptation signal travel, while metformin both impairs adaptation and independently protects muscle from damage — so a single "protection" tag cannot be treated as a benefit on the exercised-muscle endpoint.

Receipt 1: Konopka et al., Influence of Sodium Glucose Cotransporter 2 Inhibition on Physiological Adaptation to Endurance Exercise Training (J Clin Endocrinol Metab, 2019; doi:10.1210/jc.2018-01741) — 12-week RCT, n=30 sedentary overweight/obese adults; dapagliflozin (≤10 mg/d) + supervised endurance training preserved favorable body-mass, body-composition, and VO₂peak adaptations.

Receipt 2: Metformin Protects Rat Skeletal Muscle from Physical Exercise-Induced Injury (Biomedicines, 2023; doi:10.3390/biomedicines11092334) — healthy rats, 8 weeks metformin + moderate daily exercise; reduced serum muscle-injury markers (ALT/AST/LDH/CK-MB) and blunted histological damage versus untreated exercising rats.

Why surprising: Two studies launched from overlapping anchors ("antidiabetes drug + endurance exercise") diverge on the exercised muscle itself. Receipt 1 shows the SGLT2i does not block the training response; Receipt 2 shows metformin reduces exercise-induced muscle damage markers — a "protective" signal that sits next to, not inside, the adaptation literature reporting metformin attenuates training gains (as flagged in Receipt 1's framing). The two endpoints (performance adaptation vs. damage markers) cannot be merged under one "helpful" verdict.

Caveats / Falsifiers: (a) Receipt 2 is rodent, healthy, 8 weeks — not a human performance or adaptation trial; (b) reduced CK-MB/LDH is a damage marker signal, not an established functional or clinical endpoint and does not by itself demonstrate improved muscle performance; (c) species, dose, and training-intensity mismatches to Receipt 1 preclude direct ranking; (d) Receipt 1's own intro cites metformin attenuating adaptation, meaning the "Met = protective" framing in Receipt 2 is silent on that adjacent adverse finding.

Selection basis: Chosen because the pair holds the anchor constant (antidiabetes drug + endurance exercise) while the compound changes, isolating drug identity as the variable behind opposite-sign results on related but non-identical endpoints.

Next test / gap: A head-to-head rodent protocol measuring, in the same animals, both endurance-training adaptation (VO₂max, mitochondrial markers) and exercise-induced muscle damage (CK-MB, histology) under metformin vs. dapagliflozin vs. vehicle — to test whether metformin's damage-marker reduction coexists with attenuated adaptation in the same cohort, or whether the protection and attenuation signals are dissociable.